

PERSONAL INFORMATION **Karel Everaert**

WORK EXPERIENCE

-
- October 1988- Present **Head of Clinics**
Ghent University Hospital (Belgium)
Functional urology
- January 2017- Present **Full professor**
Ghent University (Belgium)
Neuro-urology
Master internship Urology
- October 2019- Present **Chairman sector Man/Woman/Child**
Ghent University Hospital (Belgium)
managerial

EDUCATION AND TRAINING

-
- **MD, PhD**
Ghent University (Belgium)

ADDITIONAL INFORMATION

-
- Expertise** Functional Urology, Urogynaecology, Andrology, Urinary tract infections
- Publications**
1. Enuresis nocturna provoked by an obstructive sleep apnea syndrome. Everaert K., Pervernagie D., Oosterlinck W. J Urol 1995; 153: 1236.
 2. Experience with clam augmentation cystoplasty in neurogenic bladder. Mast P., Hoebeke P., Oosterlinck W., Wyndaele J.J., Everaert K., Paraplegia 1996; 33:540-4.
 3. Urinary incontinence in brain injury. K. Oostra, K. Everaert, M. Van Laere, Brain Injury, 1995, 10, 459-464.
 4. The diagnostic value of the alpha-1-microglobuline and the prostate specific antigen in diagnosis and localisation of a urinary tract infection in neurogenic bladder disease. K. Everaert, K. Oostra, J. Delanghe, M. Van Laere, W. Oosterlinck. Spinal Cord 1998; 36: 33-8
 5. Urodynamic evaluation of neuromodulation in patients with voiding dysfunction. K. Everaert, H. Plancke, W. Oosterlinck. British Journal of Urology 1997; 79: 702-7.
 6. Increasing tubular proteinuria, albuminuria and decreasing urinary NAG activity following unilateral total ureteral obstruction in rats. K. Everaert, J. Delanghe, N. Lameire, W. Kerchaert, W. Sturley, C. Vande Wiele, R. Dierckx, W Oosterlinck. Urol Research 1998; 26:258-9.
 7. The urinary alpha-1-microglobuline detect uropathy. A prospective study in 483 patients. K. Everaert, J. Delanghe, W. Buylaert, C. Vande Wiele, P. Hoebeke, RA Dierckx, W. Oosterlinck. Clin Chem Lab Med 1998; 36: 309-15.
 8. Differential renal function measured by 99-Tc-m DTPA and 99-Tc-m DMSA in a complete unilateral renal obstruction rat model. C. Van De Wiele, K. Everaert, H. Van Der Eecken, JP Van Haelst, M. Simons, RA Dierckx Nucl Med Com 1997; 18: 1036-9.
 9. Fertilization, pregnancy and embryo implantation rates after ICSI with fresh or frozen-thawed testicular spermatozoa. De Croo I, Van der Elst J., Everaert K., De Sutter P., Dhont M. Hum Reprod,

1998; 13: 1893-1897.

10. Optimizing background correction when calculating differential renal function in the presence of hydronephrosis using ⁹⁹Tc-mDTPA. C. Van de Wiele, C. De Sadeleer, M. Koole, Y D'Asseler, K Everaert R.A. Dierckx. Nucl Med Com 1998; 19: 251-255.

11. The combined use of urinary alpha-1-microglobulin and Tc-99m DMSA scintigraphy in the diagnosis and follow-up of acute pyelonephritis in children. K. Everaert, P. Hoebeke, A. Raes, J. Delanghe, W. Samyn, C. Vande Wiele, J. Vande Walle. Eur J Urol 1998; 34: 486-91.

12. Age and sex-related ⁹⁹Tc-m DMSA renal uptake at 24h in children with a normal scintigram. C. Van De Wiele, M. Simons, J. Vande Walle, J. De Sutter, K. Everaert, RA Dierckx. Nucl Med Com 1998; 19: 149-154.

13. Assessment of lower urinary tract in children with non-neuropathic bladder-sphincter dysfunction. P. Hoebeke, K. Everaert, J. Vande Walle, E. Van Gool. Eur J Urol 1998; 35:57-69.

14. Urinary excretion of tubular proteins and the Tc-99m DMSA absolute renal uptake in partial ureteral obstruction in rats; a functional evaluation of hydronephrotic kidneys K. Everaert, C. Van de Wiele, J. Delanghe, H. Vander Eecken, J.P. Van Haelst, J. Van de Voorde, R.A. Dierckx, W. Oosterlinck. Urol Research 1999; 27:127-133.

15. Urinalysis by flow cytometry compared with dipstick testing. M. Langlois, J. Delanghe, S. Steyaert, K. Everaert, M. De Buyzere. Clin Chem 1999; 45:118-22.

16. Urodynamic assessment of voiding dysfunction and dysfunctional voiding in girls and women. K. Everaert, E. Van Laecke, M. De Muynck, H. Peeters, P. Hoebeke. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(4):254-64.

17. Patient satisfaction and complications following sacral root stimulation for voiding dysfunction, incontinence and perineal pain. K. Everaert, L. Baert, W. Oosterlinck, JJ. Wyndaele. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(4):231-5; discussion 236.

18. A review on urinary proteins in outflow disease of the upper urinary tract. K. Everaert, P. Hoebeke, J. Delanghe. Acta Clin Chim, 2000; 297:183-9.

19. Bilateral S3 nerve stimulation, a minimal invasive alternative treatment for postoperative stress urinary incontinence after implantation of an anterior root stimulator with posterior rhizotomy. Preliminary Communication. Spinal Cord, 2000;38:262-264.

20. Fertilization, pregnancy and embryo implantation rates after ICSI in cases of obstructive and non-obstructive azoospermia. I. De Croo, J. Van der Elst, K. Everaert, P. De Sutter, M. Dhont. Hum Reprod, 2000;15:1383-1388.

21. Evaluation of the use of Uroath-gel catheters for intermittent self-catheterization by male patients using conventional catheters for a long time. JJ. Wyndaele, D. De Ridder, K. Everaert, A. Heilporn, B. Congard-Chassol. Spinal Cord 2000; 38:97-99.

22. Bladder neck closure for treating pediatric incontinence. P. Hoebeke, P. De Kuyper, H. Goeminne, E. Van laecke, K. Everaert. Eur Urol 2000; 38:543-456.

23. The pain cycle: implications for the diagnosis and treatment of pelvic pain syndromes. Everaert K, Devulder J, De Muynck M, Stockman S, Depaep H, De Looze D, Van Buyten J, Oosterlinck W. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(1):9-14.

24. Impact of urinary tract infection and detrusor pressure on renal tubular function in patients with vesicoureteral reflux. Everaert K, Van Laecke E, Dekuyper P, Hoebeke P, Delanghe J, Oosterlinck W, Vande Walle J. Eur Urol. 2001 Mar;39(3):337-42.

25. Hoebeke P, Van Laecke E, Everaert K, Renson C, De Paepe H, Raes A, Vande Walle J. Transcutaneous neuromodulation for the urge syndrome in children: a pilot study.

J Urol. 2001;166:2416-9.

26. De Ganck J, Everaert K, Van Laecke E, Oosterlinck W, Hoebeke P.

A high easy-to-treat complication rate is the price for a continent stoma.

BJU Int. 2002 ;90:240-3.

26. Urinary plasma protein patterns in acute prostatitis. Everaert K, Delanghe J, Vanderkelen M, Cornelis K, De Wachter S, Viaene A, De Ruyck E, Clarysse B, Oosterlinck W. Clin Chem Lab Med 2003;41:79-84.

27. Post hysterectomy retention, extensive diagnostic evaluation and sacral nerve stimulation. Everaert K, De Muynck M, Rimbaut S, Weyers S. *Brit J Urol* 2003;91:497-501.
28. Urinary infections in patients with spinal cord injury. Penders J, Huylenbroeck A, Everaert K, Van Laere M, Verschraegen G. *Spinal Cord* 2003;41:549-552.
29. Chronic prostatitis and male accessory gland infection is there an impact on male infertility (diagnosis and therapy)? Everaert K, Mahmoud A, Comhaire F. *Andrologia* 2003, 35;325-30.
30. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A. *BJU Int.* 2004 Feb;93(3):303-10.
31. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. *Eur Urol* 2004; 45(5):649-54.
32. Reply to Vaidyanathzn et al. *Spinal Cord* 2004;42(11):661.
33. Induction of spermatogenesis in azoospermic men after internal spermatic vein embolization for the treatment of varicocele. Gat Y, Bachar G, Everaert K, Levinger U, Gornish M. *Human reproduction* 2005; 20(4):1013-7.
34. Sacral Nerve Stimulation: Interstim Therapy. Peeren F, Hoebeke P, Everaert K. *Expert Rev Med Dev* 2005; 2(3):253-258.
35. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. De Ridder DJ, Everaert K, Fernandez LG, Valero JV, Duran AB, Abrisqueta ML, Ventura MG, Sotillo AR. *Eur Urol.* 2005;48(6):991-5.
36. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF; Botox Detrusor Hyperreflexia Study Team. *J Urol.* 2005;174(1):196-200.
37. Improving the global management of the neurogenic bladder patient: part I. The complexity of patients. Denys P, Corcos J, Everaert K, Chartier-Kastler E, Fowler C, Kalsi V, Nitti V, Schulte-Baukloh H, Schurch B. *Curr Med Res Opin.* 2006 Feb;22(2):359-65.
38. Everaert K. Clinical issue with potential severe medical and legal complications: sacral nerve stimulation and MRI. *Eur Urol.* 2006 Aug;50(2):315-6. No abstract available.
39. Denys P, Corcos J, Everaert K, Chartier-Kastler E, Fowler C, Kalsi V, Nitti V, Schulte-Baukloh H, Schurch B. Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies. *Curr Med Res Opin.* 2006 May;22(5):851-60. Review.
40. Penders J, Fiers T, Everaert K, Barth J, Dhondt AW, Delanghe JR. Diagnostic performance of combined specific urinary proteins and urinary flow cytometry in urinary tract pathology. *Clin Chem Lab Med.* 2007;45(4):499-504.
41. Vanden Broucke H, Everaert K, Peersman W, Claes H, Vanderschueren D, Van Kampen M. Ejaculation latency times and their relationship to penile sensitivity in men with normal sexual function. *J Urol.* 2007 Jan;177(1):237-40.
42. Vereecke HE, Vanluchene AL, Mortier EP, Everaert K, Struys MM. The effects of ketamine and rocuronium on the A-Line auditory evoked potential index, Bispectral Index, and spectral entropy monitor during steady state propofol and remifentanil anesthesia. *Anesthesiology.* 2006 Dec;105(6):1122-34.
43. Chartier-Kastler E, Castro-Diaz D, De Ridder D, Everaert K, Sievert KD, Spinelli M, van Kerrebroeck P. Update on the second line management of idiopathic overactive bladder. *Prog Urol.* 2009 Sep;19(8):530-7. Epub 2009 Mar 19. Review. French.
44. Everaert K, Lumen N, Kerckhaert W, Willaert P, van Driel M. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. *Acta Clin Belg.* 2009 Jul-Aug;64(4):335-40. Review.
45. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C. Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. *J Urol.* 2010

Dec;184(6):2416-22. Epub 2010 Oct 16.

46. De Troyer B, Van Laecke E, Groen LA, Everaert K, Hoebeke P. A comparative study between continent diversion and bladder neck closure versus continent diversion and bladder neck reconstruction in children. *J Pediatr Urol.* 2011, 7(2):209-127(2):209-12.
47. Everaert K, de Waard WI, Van Hoof T, Kiekens C, Mulliez T, D'herde C. Neuroanatomy and neurophysiology related to sexual dysfunction in male neurogenic patients with lesions to the spinal cord or peripheral nerves. *Spinal Cord.* 2010 Mar;48(3):182-91. Epub 2010 Jan 5. Review.
48. Amend B, Castro-Diaz D, Chartier-Kastler E, De Ridder D, Everaert K, Spinelli M, van Kerebroeck P, Sievert KD. Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A. *Urologe A.* 2010 Feb;49(2):245-52.
49. de Waard, W.I.Q., Viaene, A., Everaert, K. Autonomic Dysreflexia after Manipulation of the Scrotum. *Curr Urol* 2010;4:52-53
50. Vanlangenhove P, De Keukeleire K, Everaert K, Van Maele G, Defreyne L. Efficacy and Safety of Two Different n-Butyl-2-Cyanoacrylates for the Embolization of Varicoceles: A Prospective, Randomized, Blinded Study. *Cardiovasc Intervent Radiol.* 2012 Jun;35(3):598-606
51. Urinary tract infections in patients with spinal cord injuries. D'Hondt F, Everaert K. *Curr Infect Dis Rep.* 2011 Dec;13(6):544-51.
52. De Troyer B, Van Laecke E, Groen LA, Everaert K, Hoebeke P. A comparative study between continent diversion and bladder neck closure versus continent diversion and bladder neck reconstruction in children. *J Pediatr Urol.* 2011, 7(2):209-127(2):209-12.
53. The AdVance male sling as a minimally invasive treatment for intrinsic sphincter deficiency in patients with neurogenic bladder sphincter dysfunction: a pilot study. Luitzen-Albert Groen, Anne-Françoise Spinoit, Piet Hoebeke, Erik Van Laecke, Bart De Troyer, Karel Everaert. *Neuro Urol & Urodyn. Neurourol Urodyn.* 2012 Nov;31(8):1284-7.
54. Qualitative detection of desmopressin in plasma by liquid 5 chromatography tandem mass spectrometry. Simone Esposito S; Deventer K, TSjoen G, Vantilborgh A, Delbeke F, Goessaert A, Everaert K, Van Eenoo P. *Anal Bioanal Chem.* 2012 Mar;402(9):2789-96
55. Sacral neuromodulation with an Implantable Pulse Generator in children with a voiding disorder: a pilot study. Luitzen-Albert Groen, Nele Loret, Piet Hoebeke, Erik Van Laecke, Johan Vande Walle, Karel Everaert. *J Urol.* 2012 Oct;188(4):1313-7.
56. Botulinum toxin for the treatment of neurogenic bladder overactivity due to spinal cord injury or multiple sclerosis. Goessaert A, Everaert K. *Expert Rev Neurother.* 2012 Jul;12(7):763-75
57. NO-touch intermittent catheterization: caregiver point of view on sterility errors, duration, comfort and costs. Goessaert A, Pieters R, Everaert K. *J Adv Nurs.* 2013 Sep;69(9):2000-7
58. Tolerance of glue embolization under local anesthesia in varicoceles: A comparative study of two different cyanoacrylates. Vanlangenhove P, Everaert K, Van Maele G, Defreyne L. *Eur J Radiol.* 2014 Mar;83(3):559-63.
59. Nocturnal polyuria in a nursing home and effect on quality of life. Goessaert AS, Denys MA, Deryckere S, Everaert K. *J Am Geriatr Soc.* 2013 Oct;61(10):1812-3.
60. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, Vik V, Ridder A, Snijder R, Yamaguchi O; BLOSSOM Investigator Group. *Neurourol Urodyn.* 2013 Nov;32(8):1116-22.
61. Long-Term Followup of Children with Nocturnal Enuresis-Increased Frequency of Nocturia in Adulthood. Goessaert AS, Schoenaers B, Opdenakker O, Hoebeke P, Everaert K, Walle JV
62. Arterial hypertension related to the injection of onabotulinumtoxinA in the detrusor. Everaert K, Goessaert AS, Vande Walle J. *Acta Clin Belg.* 2014 Mar-Apr;69(2):122-4.
63. Le traitement par onabotulinumtoxin A (BOTOX®) améliore l'incontinence urinaire et la qualité de vie des patients porteurs d'hyperactivité Vésicale idiopathique indépendamment des infections urinaires ou du recours à l'autosondage. Chartier-Kastler E, Everaert K, Gruenenfelder J, Schulte-Baukloh H, Guard S, Zheng Y, Sussman D. *Prog Urol.* 2014 Nov;24(13):797-8.
64. Pharmacokinetics and Pharmacodynamics of the Oral Disintegrating Tablet of Desmopressin in Adults with Nocturnal Polyuria: A Pilot Study. Goessaert AS, Everaert K, Hoebeke P, Vande Walle J. *Adv Ther.* 2015 Sep;32(9):799-808

65. Nocturnal Polyuria: Excess of Nocturnal Urine Production, Excess of Definitions-Influence on Renal Function Profile. Goessaert AS, Walle JV, Bosch R, Hoebeke P, Everaert K. *J Urol*. 2015 Sep 26.
66. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials. Everaert K, Gruenenfelder J, Schulte-Baukloh H, Egerdie RB, Khalaf K, Joshi M, Ni Q, Sussman D. *Int J Urol*. 2015 Dec;22(12):1131-7.
67. Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. De Caestecker K, Lumen N, Spinoit AF, Everaert K, Fiers T, Oosterlinck W. *Acta Clin Belg*. 2015 Aug
68. Would a new definition and classification of nocturia and nocturnal polyuria improve our management of patients? ICI-RS 2014. Bosch JL, Everaert K, Weiss JP, Hashim H, Rahnama'i MS, Goessaert AS, Aizen J. *Neurourol Urodyn*. 2015 Apr 10. A randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of stress urinary incontinence in females.
69. A randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of stress urinary incontinence in females. Wyndaele JJ, De Wachter S, Tommaselli GA, Angioli R, de Wildt MJ, Everaert KC, Michielsen DP, Van Koeveeringe GA. *Neurourol Urodyn*. 2015 Jan 16.
70. Secondary infertility caused by a midline cyst of the prostate. Dewaele T, D'Hooghe L, Everaert K, Devisschere P. *JBR-BTR*. 2014 Sep-Oct;97(5):317.
71. Pathophysiology, diagnosis and treatment of varicoceles: a review. Vanlangenhove P, Dhondt E, Everaert K, Defreyne L. *Minerva Urol Nefrol*. 2014 Dec;66(4):257-82. Epub 2014 Nov 14. Review.
72. Nocturnal enuresis and nocturia, differences and similarities - lessons to learn? Goessaert AS, Everaert K, Hoebeke P, Kapila A, Walle JV. *Acta Clin Belg*. 2015 Apr;70(2):81-6.
73. Diagnosing the pathophysiologic mechanisms of nocturnal polyuria. Goessaert AS, Krott L, Hoebeke P, Vande Walle J, Everaert K. *Eur Urol*. 2015 Feb;67(2):283-8.
74. Exploring nocturia: gender, age, and causes. Goessaert AS, Krott L, Walle JV, Everaert K. *Neurourol Urodyn*. 2015 Aug;34(6):561-5.
75. Pharmacokinetics and Pharmacodynamics of the Oral Disintegrating Tablet of Desmopressin in Adults with Nocturnal Polyuria: A Pilot Study. Goessaert AS, Everaert K, Hoebeke P, Vande Walle J. *Adv Ther*. 2015 Sep;32(9):799-808. doi: 10.1007/s12325-015-0247-8. Epub 2015 Sep 28.
76. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials. Everaert K, Gruenenfelder J, Schulte-Baukloh H, Egerdie RB, Khalaf K, Joshi M, Ni Q, Sussman D. *Int J Urol*. 2015 Dec;22(12):1131-7. doi: 10.1111/iju.12912. Epub 2015 Sep 22.
77. Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. Hanna-Mitchell AT, Robinson D, Cardozo L, Everaert K, Petkov GV. *Neurourol Urodyn*. 2016 Feb;35(2):299-303. doi: 10.1002/nau.22809. Review.
78. Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Denys MA, Anding R, Tubaro A, Abrams P, Everaert K. *Neurourol Urodyn*. 2016 Feb;35(2):278-82. doi: 10.1002/nau.22765. Review
- Circadian Rhythms in Water and Solute Handling in Adults with a Spinal Cord Injury. Denys MA, Viaene A, Goessaert AS, Vanhaverbeke F, Hoebeke P, Raes A, Everaert K. *J Urol*. 2016 Aug 6. pii: S0022-5347(16)30966-1. doi: 10.1016/j.juro.2016.08.001. [Epub ahead of print]
79. Jones J, Van de Putte D, De Ridder D, Knowles C, O'Connell PR, Nelson D, Goessaert AS, Everaert K. *Urology*. 2016 May 24. pii: S0090-4295(16)30233-3. doi: 10.1016/j.urology.2016.05.032. [Epub ahead of print] Review.
80. Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. Hanna-Mitchell AT, Robinson D, Cardozo L, Everaert K, Petkov GV. *Neurourol Urodyn*. 2016 Feb;35(2):299-303. doi: 10.1002/nau.22809. Review.
81. Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Denys MA, Anding R, Tubaro A, Abrams P, Everaert K. *Neurourol Urodyn*. 2016 Feb;35(2):278-82. doi:

10.1002/nau.22765. Review.

82. Nocturnal Polyuria: Excess of Nocturnal Urine Production, Excess of Definitions-Influence on Renal Function Profile. Goessaert AS, Walle JV, Bosch R, Hoebeke P, Everaert K. *J Urol*. 2016 Mar;195(3):670-6. doi: 10.1016/j.juro.2015.09.076. Epub 2015 Sep 26.
83. Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. De Caestecker K, Lumen N, Spinoit AF, Everaert K, Fiers T, Oosterlinck W. *Acta Clin Belg*. 2016 Jun 9:1-3. [Epub ahead of print]
84. Would a new definition and classification of nocturia and nocturnal polyuria improve our management of patients? ICI-RS 2014. Bosch JL, Everaert K, Weiss JP, Hashim H, Rahnama'i MS, Goessaert AS, Aizen J. *Neurourol Urodyn*. 2016 Feb;35(2):283-7. doi: 10.1002/nau.22772. Epub 2015 Apr 10.
85. A randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of stress urinary incontinence in females. Wyndaele JJ, De Wachter S, Tommaselli GA, Angioli R, de Wildt MJ, Everaert KC, Michielsen DP, Van Koeveringe GA. *Neurourol Urodyn*. 2016 Feb;35(2):252-9. doi: 10.1002/nau.22708. Epub 2015 Jan 16.
86. Persistent urinary incontinence after a robot-assisted artificial urinary sphincter procedure: lessons learnt from two cases. Hervé F, Lumen N, Goessaert AS, Everaert K. *BMJ Case Rep*. 2016 Oct 25;2016. pii: bcr2016216971. doi: 10.1136/bcr-2016-216971.
87. The impact of nocturnal polyuria in older people with nocturnal LUTS. Lopes Mendes AL, Decalf V, Denys MA, Tubaro A, Everaert K. *Minerva Urol Nefrol*. 2017 Aug;69(4):377-383. doi: 10.23736/S0393-2249.16.02745-4. Epub 2016 Oct 5.
88. Evaluation of the occurrence and diagnose definitions for Nocturnal Polyuria in Spinal Cord Injured patients during rehabilitation. Viaene A, Denys MA, Goessaert AS, Claeys J, Raes A, Roggeman S, Everaert K. *Eur J Phys Rehabil Med*. 2017 Nov 3. doi: 10.23736/S1973-9087.17.04851-1. [Epub ahead of print]
89. An exploratory pilot study with copeptin as a biomarker for individualizing treatment for nocturnal polyuria. Bruneel E, Goessaert AS, Denys MA, Juul KV, Nørgaard JP, Everaert K. *Low Urin Tract Symptoms*. 2017 Oct 23. doi: 10.1111/luts.12192. [Epub ahead of print]
90. A practical approach to the management of nocturia. Oelke M, De Wachter S, Drake MJ, Giannantoni A, Kirby M, Orme S, Rees J, van Kerrebroeck P, Everaert K. *Int J Clin Pract*. 2017 Nov;71(11). doi: 10.1111/ijcp.13027. Epub 2017 Oct 5.
91. Video Urodynamic Study in Female Adults With Air-filled Catheters: A Health-care Training Video. Decalf V, Ragolle I, Ploumidis A, Hoebeke P, Everaert K, Spinoit AF. *Urology*. 2017 Oct;108:239-240. doi: 10.1016/j.urology.2017.06.012. Epub 2017 Jul 3.
92. Clean Intermittent Self-Catheterization as a Treatment Modality for Urinary Retention: Perceptions of Urologists. Weynants L, Hervé F, Decalf V, Kumps C, Pieters R, Troyer B, Everaert K. *Int Neurourol J*. 2017 Sep;21(3):189-196. doi: 10.5213/inj.1734824.412. Epub 2017 Sep 12.
93. Pathophysiology of nocturnal lower urinary tract symptoms in older patients with urinary incontinence. Denys MA, Decalf V, Kumps C, Petrovic M, Goessaert AS, Everaert K. *Int J Urol*. 2017 Nov;24(11):808-815. doi: 10.1111/iju.13431. Epub 2017 Aug 16.
94. A different way to study frequency volume charts in patients with nocturia. Denys MA, Goessaert AS, Dejaeghere B, Decalf V, Hoebeke P, Everaert K. *Neurourol Urodyn*. 2017 Jul 10. doi: 10.1002/nau.23344. [Epub ahead of print]
95. Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment. Decalf VH, Huion AMJ, Benoit DF, Denys MA, Petrovic M, Everaert KCM. *Drugs Aging*. 2017 Aug;34(8):615-623. doi: 10.1007/s40266-017-0474-6.
96. Minimal Device Encrustation on Vesair Intravesical Balloons in the Treatment of Stress Urinary Incontinence: Analysis of Balloons Removed from Women in the SOLECT Trial. van Koeveringe GA, De Wachter S, Zuckerman JM, Tommaselli G, de Wildt MJ, Everaert KCM, Michielsen DPJ, Wyndaele JJ. *Adv Ther*. 2017 Jul;34(7):1686-1694. doi: 10.1007/s12325-017-0570-3. Epub 2017 Jun 9.
97. Outcome of Anterior Lumbar Interbody Fusion: A Retrospective Study of Clinical and Radiologic

- Parameters. Pinson H, Hallaert G, Herregodts P, Everaert K, Couvreur T, Caemaert J, Kalala JP, Van Roost D. *World Neurosurg.* 2017 Jul;103:772-779. doi: 10.1016/j.wneu.2017.04.077. Epub 2017 Apr 20.
98. OnabotulinumtoxinA injections in detrusor facilitate self-catheterisation in a patient with paraplegia and bladder outlet dyssynergia. Hervé F, Viaene A, Everaert K. *BMJ Case Rep.* 2017 Apr 6;2017. pii: bcr-2016-218429. doi: 10.1136/bcr-2016-218429.
99. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. Herschorn S, Kohan A, Aliotta P, McCammon K, Sriram R, Abrams S, Lam W, Everaert K. *J Urol.* 2017 Jul;198(1):167-175. doi: 10.1016/j.juro.2017.01.069. Epub 2017 Feb 1.
100. Circadian Variation in Post Void Residual in Nursing Home Residents With Moderate Impairment in Activities of Daily Living. Decalf V, Huion A, Denys MA, Kumps C, Petrovic M, Everaert K. *J Am Med Dir Assoc.* 2017 May 1;18(5):433-437. doi: 10.1016/j.jamda.2016.11.022. Epub 2017 Jan 17.
101. Basic or extended urine sampling to analyse urine production? Denys MA, Kapila V, Weiss J, Goessaert AS, Everaert K. *Neurourol Urodyn.* 2017 Sep;36(7):1867-1875. doi: 10.1002/nau.23198. Epub 2017 Jan 5.
102. An exploratory pilot study with copeptin as a biomarker for individualizing treatment for nocturnal polyuria. Bruneel E, Goessaert AS, Denys MA, Juul KV, Nørgaard JP, Everaert K. *Low Urin Tract Symptoms.* 2019 Jan;11(1):43-47. doi: 10.1111/luts.12192. Epub 2017 Oct 23.
103. Evaluation of the occurrence and diagnose definitions for nocturnal polyuria in spinal cord injured patients during rehabilitation. Viaene A, Denys MA, Goessaert AS, Claeys J, Raes A, Roggeman S, Everaert K. *Eur J Phys Rehabil Med.* 2019 Feb;55(1):40-46. doi: 10.23736/S1973-9087.17.04851-1. Epub 2017 Nov 3.
104. Systematic review of proposed definitions of nocturnal polyuria and population-based evidence of their diagnostic accuracy. Olesen TK, Denys MA, Vande Walle J, Everaert K. *Acta Clin Belg.* 2018 Aug;73(4):268-274. doi: 10.1080/17843286.2018.1427821. Epub 2018 Feb 6.
105. Nocturia is more bothersome than daytime LUTS: Results from an Observational, Real-life Practice Database including 8659 European and American LUTS patients. Everaert K, Anderson P, Wood R, Andersson FL, Holm-Larsen T. *Int J Clin Pract.* 2018 Jun;72(6):e13091. doi: 10.1111/ijcp.13091. Epub 2018 May 16.
106. Validated uroflowmetry-based predictive model for the primary diagnosis of urethral stricture disease in men. Lambert E, Denys MA, Poelaert F, Everaert K, Lumen N. *Int J Urol.* 2018 Sep;25(9):792-798. doi: 10.1111/iju.13730. Epub 2018 Jul 18.
107. Questions to ask a patient with nocturia. Bower WF, Everaert K, Ong TJ, Ervin CF, Norgaard JP, Whishaw M. *Aust J Gen Pract.* 2018 Jul;47(7):465-469.
108. How can we develop a more clinically useful and robust algorithm for diagnosing and treating nocturia? ICI-RS 2017. Everaert K, Hervé F, Bower W, Djurhuus JC, Dmochowski R, Fine N, Wein A, Wyndaele M, Weiss J. *Neurourol Urodyn.* 2018 Jun;37(S4):S46-S59. doi: 10.1002/nau.23569.
109. Smart diapers for nursing home residents with dementia: a pilot study. Huion A, Decalf V, Kumps C, De Witte N, Everaert K. *Acta Clin Belg.* 2018 Aug 27:1-5. doi: 10.1080/17843286.2018.1511279. [Epub ahead of print]
110. Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome. Monaghan TF, Suss NR, Epstein MR, Flores VX, Wu ZD, Michelson KP, Hervé F, Bliwise DL, Everaert K, Weiss JP. *Eur Urol Focus.* 2018 Nov 1. pii: S2405-4569(18)30316-X. doi: 10.1016/j.euf.2018.10.015. [Epub ahead of print]
111. Effect of diuresis on bother related to lower urinary tract symptoms. Hervé F, Delabie L, Mylle T, Weiss J, Bower W, Everaert K. *Int J Clin Pract.* 2018 Nov 29:e13299. doi: 10.1111/ijcp.13299. [Epub ahead of print]
112. Initial clinical experience with selective bladder denervation for refractory overactive bladder. Tu LM, De Wachter S, Robert M, Dmochowski RR, Miller LE, Everaert K. *Neurourol Urodyn.* 2019 Feb;38(2):644-652. doi: 10.1002/nau.23881. Epub 2018 Nov 29.

113. Development of a multivariate prediction model for nocturia, based on urinary tract etiologies. Olesen TK, Denys MA, Goessaert AS, Bruneel E, Decalf V, Helleputte T, Paul J, Grampe P, Everaert K. *Int J Clin Pract*. 2018 Dec 16:e13306. doi: 10.1111/ijcp.13306. [Epub ahead of print]
114. International Continence Society consensus on the diagnosis and treatment of nocturia. Everaert K, Hervé F, Bosch R, Dmochowski R, Drake M, Hashim H, Chapple C, Van Kerrebroeck P, Mourad S, Abrams P, Wein A. *Neurourol Urodyn*. 2019 Feb;38(2):478-498. doi: 10.1002/nau.23939. Epub 2019 Feb 19.
115. Conservative treatment for leg oedema and the effect on nocturnal polyuria in patients with spinal cord injury. Viaene A, Roggeman S, Goessaert AS, Kessler TM, Mehnert U, Besien VV, De Muynck M, Everaert K. *BJU Int*. 2019 Jan 17. doi: 10.1111/bju.14672. [Epub ahead of print]
116. Assessment of Intermittent Self-Catheterization Procedures in Patients with Neurogenic Lower Urinary Tract Dysfunction: Dutch Translation and Validation of the Intermittent Catheterization Satisfaction Questionnaire, Intermittent Catheterization Acceptance Test, Intermittent Self Catheterization Questionnaire and Intermittent Catheterization Difficulty Questionnaire. Hervé F, Ragolle I, Amarenco G, Viaene A, Guinet-Lacoste A, Bonniaud V, Everaert K. *Urol Int*. 2019;102(4):476-481. doi: 10.1159/000499884. Epub 2019 Apr 18.
117. Nocturnal voiding frequency does not describe nocturia-related bother. Rose GE, Denys MA, Kumps C, Whishaw DM, Khan F, Everaert KC, Bower WF. *Neurourol Urodyn*. 2019 Aug;38(6):1648-1656. doi: 10.1002/nau.24029. Epub 2019 Jun 4.
118. The OptiLUTS trial: improving care for therapy-resistant symptoms of the pelvis in Belgium. Ghijssels L, Van De Putte D, Hervé F, Goessaert AS, Beeckman D, Pattyn P, Everaert K. *Acta Clin Belg*. 2019 Jun 18:1-6. doi: 10.1080/17843286.2019.1630109. [Epub ahead of print]
119. Toileting-related falls at night in hospitalised patients: The role of nocturia. Rose G, Decalf V, Everaert K, Bower WF. *Australas J Ageing*. 2019 Jul 18. doi: 10.1111/ajag.12696. [Epub ahead of print]
120. Dutch version of the TANGO nocturia screening tool: cross-culturally translation and reliability study in community-dwelling people and nursing home residents. Decalf V, Everaert K, De Witte N, Petrovic M, Bower W. *Acta Clin Belg*. 2019 Aug 10:1-8. doi: 10.1080/17843286.2019.1653511. [Epub ahead of print]
121. Prevalence and characteristics of incident falls related to nocturnal toileting in hospitalized patients. Decalf V, Bower W, Rose G, Petrovic M, Pieters R, Eeckloo K, Everaert K. *Acta Clin Belg*. 2019 Sep 3:1-6. doi: 10.1080/17843286.2019.1660022. [Epub ahead of print]
122. The effect of a multidisciplinary weight loss program on renal circadian rhythm in obese adolescents. Pauwaert K, Dejonckheere S, Bruneel E, Van Der Jeugt J, Keersmaekers L, Roggeman S, De Guchteneere A, Vande Walle J, Everaert K. *Eur J Pediatr*. 2019 Sep 5. doi: 10.1007/s00431-019-03456-y. [Epub ahead of print]
123. Haptoglobin 1-1 phenotype: A risk factor for 24-h polyuria. Alwis US, Roggeman S, Monaghan TF, Denys MA, Everaert K, Delanghe J. *Int J Clin Pract*. 2019 Sep 11. doi: 10.1111/ijcp.13419. [Epub ahead of print]
124. Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study. Ringoir A, Dhondt B, De Bleser E, Van Laecke E, Everaert K, Groen LA, Hoebeke P, Spinoit AF. *J Pediatr Urol*. 2019 Dec 27. pii: S1477-5131(19)30437-1. doi: 10.1016/j.jpuro.2019.12.013. [Epub ahead of print]
125. Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome. Monaghan TF, Epstein MR, Bliwise DL, Michelson KP, Wu ZD, Lazar JM, Everaert K, Kabarriti AE, Holmes A, Wein AJ, Weiss JP. *Neurourol Urodyn*. 2020 Jan 21. doi: 10.1002/nau.24283. [Epub ahead of print]
126. ICI-RS 2019 nocturia think tank: How can experimental science guide us in understanding the pathophysiology of nocturia? Vahabi B, Jabr R, Fry C, McCloskey K, Everaert K, Agudelo CW, Monaghan TF, Rahnama'i MS, Panicker JN, Weiss JP. *Neurourol Urodyn*. 2020 Jan 10. doi: 10.1002/nau.24274. [Epub ahead of print] Review.
127. Is our current understanding and management of nocturia allowing improved care? International Consultation on Incontinence-Research Society 2018. Hervé F, Abrams P, Bower W,

- De Wachter S, Epstein M, Lombardo R, Robinson D, Tubaro A, Wein A, Weiss JP, Everaert K. *Neurourol Urodyn*. 2019 Dec;38 Suppl 5:S127-S133. doi: 10.1002/nau.23961.
128. Association between nocturia and frailty among elderly males in a veterans administration population. Monaghan TF, Wagg AS, Bliwise DL, Agudelo CW, Michelson KP, Rahman SN, Epstein MR, Haddad R, Everaert K, Lazar JM, Weiss JP. *Aging Clin Exp Res*. 2019 Nov 23. doi: 10.1007/s40520-019-01416-y. [Epub ahead of print]
129. Identifying men with global polyuria on a nocturnal-only voiding diary. Monaghan TF, Rahman SN, Bliwise DL, Michelson KP, Agudelo CW, Miller CD, Weinstein CS, Olesen TK, Lazar JM, Everaert K, Verbalis JG, Weiss JP. *Neurourol Urodyn*. 2020 Jan;39(1):347-352. doi: 10.1002/nau.24210. Epub 2019 Nov 6
130. Diagnosing Nocturnal Polyuria from a Single Nocturnal Urine Sample. Monaghan TF, Verbalis JG, Haddad R, Pauwaert K, Agudelo CW, Goessaert AS, Denys MA, Lazar JM, Bliwise DL, Vande Walle J, Wein AJ, Weiss JP, Everaert K. *Eur Urol Focus*. 2019 Oct 16. pii: S2405-4569(19)30308-6. doi: 10.1016/j.euf.2019.10.002.
131. Management of Nocturia and Nocturnal Polyuria. Weiss JP, Everaert K. *Urology*. 2019 Nov;133S:24-33. doi: 10.1016/j.urology.2019.09.022. Epub 2019 Oct 2.
132. Diagnosing Nocturnal Polyuria from a Single Nocturnal Urine Sample. Monaghan TF, Verbalis JG, Haddad R, Pauwaert K, Agudelo CW, Goessaert AS, Denys MA, Lazar JM, Bliwise DL, Vande Walle J, Wein AJ, Weiss JP, Everaert K. *Eur Urol Focus*. 2020 Jul 15;6(4):738-744. doi: 10.1016/j.euf.2019.10.002. Epub 2019 Oct 16.
133. Identifying men with global polyuria on a nocturnal-only voiding diary. Monaghan TF, Rahman SN, Bliwise DL, Michelson KP, Agudelo CW, Miller CD, Weinstein CS, Olesen TK, Lazar JM, Everaert K, Verbalis JG, Weiss JP. *Neurourol Urodyn*. 2020 Jan;39(1):347-352. doi: 10.1002/nau.24210. Epub 2019 Nov 6.
134. Association between nocturia and frailty among elderly males in a veterans administration population. Monaghan TF, Wagg AS, Bliwise DL, Agudelo CW, Michelson KP, Rahman SN, Epstein MR, Haddad R, Everaert K, Lazar JM, Weiss JP. *Aging Clin Exp Res*. 2020 Oct;32(10):1993-2000. doi: 10.1007/s40520-019-01416-y. Epub 2019 Nov 23.
135. Is our current understanding and management of nocturia allowing improved care? International Consultation on Incontinence-Research Society 2018. Hervé F, Abrams P, Bower W, De Wachter S, Epstein M, Lombardo R, Robinson D, Tubaro A, Wein A, Weiss JP, Everaert K. *Neurourol Urodyn*. 2019 Dec;38 Suppl 5:S127-S133. doi: 10.1002/nau.23961.
136. ICI-RS 2019 nocturia think tank: How can experimental science guide us in understanding the pathophysiology of nocturia? Vahabi B, Jabr R, Fry C, McCloskey K, Everaert K, Agudelo CW, Monaghan TF, Rahnama'i MS, Panicker JN, Weiss JP. *Neurourol Urodyn*. 2020 Jul;39 Suppl 3:S88-S95. doi: 10.1002/nau.24274. Epub 2020 Jan 10.
137. Phenotyping nocturnal polyuria: circadian and age-related variations in diuresis rate, free water clearance and sodium clearance. Monaghan TF, Bliwise DL, Denys MA, Goessaert AS, Decalf V, Kumps C, Vande Walle J, Weiss JP, Epstein MR, Weedon J, Lazar JM, Everaert K. *Age Ageing*. 2020 Apr 27;49(3):439-445. doi: 10.1093/ageing/afz200.
138. Sodium restriction improves nocturia in patients at a cardiology clinic. Monaghan TF, Michelson KP, Wu ZD, Gong F, Agudelo CW, George CD, Alwis US, Epstein MR, Mekki P, Flores VX, Bliwise DL, Everaert K, Vande Walle J, Weiss JP, Lazar JM. *J Clin Hypertens (Greenwich)*. 2020 Apr;22(4):633-638. doi: 10.1111/jch.13829. Epub 2020 Feb 12.
139. Circadian Patterns in Postvoid Residual and Voided Percentage Among Older Women with Urinary Incontinence. Correction to: Association between nocturia and frailty among elderly males in a veterans administration population. Monaghan TF, Wagg AS, Bliwise DL, Agudelo CW, Michelson KP, Rahman SN, Epstein MR, Haddad R, Everaert K, Lazar JM, Weiss JP. *Aging Clin Exp Res*. 2020 Oct;32(10):2111. doi: 10.1007/s40520-019-01456-4.
140. The role of lower urinary tract symptoms in fall risk assessment tools in hospitals: a review. Roggeman S, Weiss JP, Van Laecke E, Vande Walle J, Everaert K, Bower WF. *F1000Res*. 2020 Apr 3;9:F1000 Faculty Rev-236. doi: 10.12688/f1000research.21581.1. eCollection 2020.
141. Overlap between nocturnal polyuria, diurnal polyuria, and 24-h polyuria among men with

nocturia. Monaghan TF, Rahman SN, Miller CD, Agudelo CW, Michelson KP, Nwannunu NA, Lazar JM, Bliwise DL, Verbalis JG, Everaert K, Blaivas JG, Wein AJ, Weiss JP. *Int Urol Nephrol*. 2020 Oct;52(10):1845-1849. doi: 10.1007/s11255-020-02502-1. Epub 2020 May 20.

142. Tolerability and safety of urotainer® polihexanide 0.02% in catheterized patients: a prospective cohort study. Pannek J, Everaert K, Möhr S, Vance W, Van der Aa F, Kesselring J. *BMC Urol*. 2020 Jul 8;20(1):92. doi: 10.1186/s12894-020-00650-1. PMID: 32641131 Free PMC article.

143. Alwis US, Haddad R, Monaghan TF, Abrams P, Dmochowski R, Bower W, Wein AJ, Roggeman S, Weiss JP, Mourad S, Delanghe J, Everaert K. *Int J Clin Pract*. 2020 Sep;74(9):e13539. doi: 10.1111/ijcp.13539. Epub 2020 Jun 9.

144. Primary care providers' knowledge about the therapeutic management of refractory pelvic floor dysfunctions in Flanders, Belgium: a cross-sectional study. Ghijssels L, Pauwaert K, Verla W, Beeckman D, Van de Putte D, Pattyn P, Everaert K. *Acta Chir Belg*. 2020 Jul 20:1-8. doi: 10.1080/00015458.2020.1794338. Online ahead of print.

145. The importance of medical student perspectives on the impact of COVID-19. Kapila V, Corthals S, Langhendries L, Kapila AK, Everaert K. *Br J Surg*. 2020 Jul 20:10.1002/bjs.11808. doi: 10.1002/bjs.11808. Online ahead of print. PMID: 32687601 Free PMC article

146. Assessment of the Most Impactful Combination of Factors Associated with Nocturia and to Define Nocturnal Polyuria by Multivariate Modelling. Olesen T, Paul J, Gramme P, Drake MJ, Vandewalle J, Everaert K. *J Clin Med*. 2020 Jul 16;9(7):2262. doi: 10.3390/jcm9072262.

147. Could Evening Dietary Protein Intake Play a Role in Nocturnal Polyuria? Alwis US, Delanghe J, Dossche L, Walle JV, Van Camp J, Monaghan TF, Roggeman S, Everaert K. *J Clin Med*. 2020 Aug 5;9(8):2532. doi: 10.3390/jcm9082532.

148. Cardiovascular risk independently predicts small functional bladder storage capacity. Monaghan TF, Miller CD, Agudelo CW, Rahman SN, Everaert K, Birder LA, Wein AJ, Weiss JP, Lazar JM. *Int Urol Nephrol*. 2020 Aug 17. doi: 10.1007/s11255-020-02616-6. Online ahead of print.

149. Associations between nighttime and daytime maximum voided volumes: Relevance for nocturia? Monaghan TF, Bliwise DL, Dmochowski RR, Lazar JM, Birder LA, Everaert K, Weiss JP. *Neurourol Urodyn*. 2020 Nov;39(8):2301-2304. doi: 10.1002/nau.24485. Epub 2020 Aug 18.

150. The science behind programming algorithms for sacral neuromodulation. Knowles CH, de Wachter S, Engelberg S, Leher P, Matzel KE, Zirpel L; European SNM Expert Group. *Colorectal Dis*. 2020 Oct 3. doi: 10.1111/codi.15390. Online ahead of print.

151. Nocturnal Urine Production in Women With Global Polyuria. Monaghan TF, Kavoussi AM, Agudelo CW, Rahman SN, Michelson KP, Bliwise DL, Lazar JM, Birder LA, Alwis US, Walle JV, Wein AJ, Blaivas JG, Weiss JP, Everaert K. *Int Neurourol J*. 2020 Sep;24(3):270-277. doi: 10.5213/inj.2040166.083. Epub 2020 Sep 30.

152. The modified nocturia index: Refining the workup for nocturia. Monaghan TF, Khargi R, Miller CD, Agudelo CW, Bruha MJ, Fink LE, Lazar JM, Everaert K, Weiss JP. *Neurourol Urodyn*. 2020 Oct 14. doi: 10.1002/nau.24545. Online ahead of print.

Projects Nocturnal polyuria research group
Bladder emptying reseach group
OptiLuts research group

Memberships EAU, ICS, BAU

Other Relevant Information reviewer J Urol, Eur Urol, NUU, Spinal Cord, ASJA, WJU